Catalyst Event
Lululemon Athletica Inc (LULU) · Earnings Release
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/17/2026, 12:00:00 AM
Lululemon reported Q4 2025 EPS of $5.01 and revenue of $3.6B on 2026-03-17, beating analyst estimates, but issued weak fiscal 2026 guidance below consensus. High importance is assigned as the guidance miss and projected North American revenue decline are estimated by analysts to cause a >10% price impact; expected.
Korean Translation
룰루레몬이 2026-03-17에 2025 회계연도 4분기 실적을 발표하며 시장 예상치를 상회했으나, 컨센서스를 하회하는 2026 회계연도 가이던스를 제시함. 부진한 가이던스와 북미 매출 감소 전망은 10% 이상의 주가 하락을 초래할 것으로 분석가들에 의해 예상됨.
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Expected FDA decision date for oral obesity drug orforglipron scheduled. High importance estimated as FDA decisions for major drugs typically cause >10% price swings.
4/10/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
The ex-dividend date for the quarterly cash dividend of $1.25 per share is March 27, 2026, representing a 3% increase over the previous quarterly dividend.
3/27/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
Annual General Meeting 2026 scheduled.
3/26/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
HSBC downgraded the stock from 'Hold' to 'Reduce' with a price target of $850, citing valuation concerns and competitive pressures.
3/22/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
Patents for semaglutide, the active ingredient in Ozempic and Wegovy, expired in key markets including China and India. This event opens the door to generic competition in those regions.
3/20/2026, 12:00:00 AM